Elevance Health partners with Plus Therapeutics for cancer screening test expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 25 2026
0mins
Source: seekingalpha
Elevance Health Inc. saw its stock rise by 5.02% as it reached a 5-day high amid a positive market reaction.
The company signed a national agreement with Plus Therapeutics' subsidiary CNSide Diagnostics to expand coverage for a cancer screening test, effective May 1, 2026. This agreement is expected to benefit approximately 45.4 million people in the U.S., significantly enhancing Elevance's market penetration and brand influence. The CNSide test will help identify tumor cell spread to the central nervous system, further solidifying Elevance's commitment to improving health outcomes.
This partnership not only strengthens Elevance Health's position in the healthcare market but also reflects investor confidence in the company's growth potential, as evidenced by the positive stock movement.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELV
Wall Street analysts forecast ELV stock price to fall
15 Analyst Rating
11 Buy
4 Hold
0 Sell
Moderate Buy
Current: 408.170
Low
332.00
Averages
389.07
High
425.00
Current: 408.170
Low
332.00
Averages
389.07
High
425.00
About ELV
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elevance Health Sues CMS Over Medicare Advantage Ratings
- Lawsuit Background: Elevance Health has filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS), alleging unfair adjustments to a competitor's Medicare Advantage Star Ratings after finalization, claiming this created an uneven competitive landscape.
- Financial Impact: Elevance estimates that the disputed CMS decision cost it approximately $115 million in Medicare Advantage quality bonus payments, directly affecting its financial performance and market competitiveness.
- Industry Implications: Should the court side with Elevance, CMS may be compelled to revisit its ratings process, potentially impacting payments and competitive positioning across the industry, which could lead to similar adjustments for other insurers.
- Future Outlook: Elevance argues that all insurers should be treated under the same rules post-rating release rather than allowing company-specific adjustments, and the outcome of this lawsuit could significantly influence the future earnings growth of insurers heavily reliant on Medicare Advantage.
See More
Plus Therapeutics Signs Agreement with Elevance Health for CNSide Assay
- Agreement Signed: Plus Therapeutics' wholly owned subsidiary CNSide Diagnostics has signed a national agreement with Elevance Health, effective May 1, 2026, marking a strategic expansion in tumor cell enumeration testing.
- Testing Platform Benefits: The CNSide CSF assay platform determines leptomeningeal metastases in patients, utilizing quantitative analyses to detect malignant cell residues, and has proven effective in the FORESEE clinical trial with 92% sensitivity and 95% specificity.
- Market Coverage Expansion: The contract with Elevance is expected to add 45.5 million users, bringing total coverage to 126 million people across the U.S., significantly enhancing market penetration and brand influence.
- Positive Stock Reaction: PSTV closed at $4.26, up 7.58%, and is trading at $4.28 in pre-market, indicating strong market expectations regarding this partnership.
See More
Plus Therapeutics Partners with Elevance Health for Cancer Screening Test Coverage Expansion
- Agreement Reached: Plus Therapeutics' subsidiary CNSide Diagnostics has signed an agreement with Elevance Health to expand coverage for a cancer screening test, allowing Elevance members to get reimbursed for the CNSide test, benefiting approximately 45.4 million people in the U.S.
- Test Overview: The CNSide test is designed to help patients identify whether their tumor cells have spread to the central nervous system, currently available exclusively through CNSide Diagnostics to U.S. healthcare professionals, enhancing market recognition of the test.
- Expanded Coverage: The agreement takes effect on May 1, 2026, and is expected to widen the test's availability to 126 million people, significantly boosting Plus Therapeutics' competitiveness in the cancer screening market.
- Market Impact: This agreement not only enhances Plus Therapeutics' market position but may also drive its stock price up, reflecting investor confidence in the company's future growth potential.
See More
Elevance Health and IFF Transform School Fitness Space
- Fitness Space Renovation: Thomas Carr Howe Middle School celebrated the transformation of its fitness and strength training area through a partnership with Elevance Health and the Impact Fitness Foundation, enhancing health and athletic opportunities for students.
- Ongoing Community Investment: This marks the fifth consecutive year that Elevance Health and IFF have invested in community fitness initiatives in Indianapolis schools, demonstrating the company's long-term commitment to youth health.
- Volunteer Engagement: More than 40 Elevance Health volunteers participated in the renovation, installing new flooring, fitness equipment, and storage systems to create a modern training environment aimed at supporting student wellness.
- Support for Female Athletes: The renovated facility will provide expanded opportunities for female student-athletes, helping them build confidence and leadership skills, reflecting Elevance Health's commitment to empowering women in sports.
See More
Elevance Health and IFF Transform School Fitness Space
- Community Fitness Investment: Elevance Health and the Impact Fitness Foundation have partnered for five consecutive years to invest in Indianapolis schools, enhancing health and athletic opportunities for students, reflecting the company's long-term commitment to youth health.
- Facility Modernization: The newly renovated fitness space features new flooring, fitness equipment, and storage systems, designed to provide middle school students with a modern training environment that promotes their health and athletic development.
- Expanded Student Opportunities: The renovated facility will support expanded strength and conditioning programs and open gym opportunities, helping students build healthy habits and creating new experiences for female athletes.
- Leadership and Confidence: The Impact Fitness Foundation emphasizes that creating welcoming athletic spaces can help young women discover confidence and leadership, fostering lifelong connections to health and fitness while enhancing overall community well-being.
See More
Elevance Health Invests $640 Million in Affordable Housing
- Significant Investment: Elevance Health has invested $640 million in affordable housing over the past five years, reinforcing its commitment to social determinants of health and supporting over 40,000 housing units, which is expected to significantly improve community health outcomes.
- Long-term Commitment: With over $1 billion invested in nearly two decades, the company demonstrates its ongoing efforts to lower total healthcare costs and expand access to safe, stable, and affordable housing, aiming to enhance overall community well-being.
- Social Impact: These investments not only provide economic support for housing development but also actively promote improvements in social health, helping more families secure stable living conditions that enhance their quality of life.
- Strategic Importance: This investment reflects the company's emphasis on social responsibility, aiming to reduce healthcare expenditures by improving housing conditions, thereby strengthening its competitive position and market standing in the healthcare industry.
See More
Elevance Health Sues CMS Over Medicare Advantage Ratings
- Lawsuit Background: Elevance Health has filed a lawsuit against the Centers for Medicare & Medicaid Services (CMS), alleging unfair adjustments to a competitor's Medicare Advantage Star Ratings after finalization, claiming this created an uneven competitive landscape.
- Financial Impact: Elevance estimates that the disputed CMS decision cost it approximately $115 million in Medicare Advantage quality bonus payments, directly affecting its financial performance and market competitiveness.
- Industry Implications: Should the court side with Elevance, CMS may be compelled to revisit its ratings process, potentially impacting payments and competitive positioning across the industry, which could lead to similar adjustments for other insurers.
- Future Outlook: Elevance argues that all insurers should be treated under the same rules post-rating release rather than allowing company-specific adjustments, and the outcome of this lawsuit could significantly influence the future earnings growth of insurers heavily reliant on Medicare Advantage.
See More
Plus Therapeutics Signs Agreement with Elevance Health for CNSide Assay
- Agreement Signed: Plus Therapeutics' wholly owned subsidiary CNSide Diagnostics has signed a national agreement with Elevance Health, effective May 1, 2026, marking a strategic expansion in tumor cell enumeration testing.
- Testing Platform Benefits: The CNSide CSF assay platform determines leptomeningeal metastases in patients, utilizing quantitative analyses to detect malignant cell residues, and has proven effective in the FORESEE clinical trial with 92% sensitivity and 95% specificity.
- Market Coverage Expansion: The contract with Elevance is expected to add 45.5 million users, bringing total coverage to 126 million people across the U.S., significantly enhancing market penetration and brand influence.
- Positive Stock Reaction: PSTV closed at $4.26, up 7.58%, and is trading at $4.28 in pre-market, indicating strong market expectations regarding this partnership.
See More
Plus Therapeutics Partners with Elevance Health for Cancer Screening Test Coverage Expansion
- Agreement Reached: Plus Therapeutics' subsidiary CNSide Diagnostics has signed an agreement with Elevance Health to expand coverage for a cancer screening test, allowing Elevance members to get reimbursed for the CNSide test, benefiting approximately 45.4 million people in the U.S.
- Test Overview: The CNSide test is designed to help patients identify whether their tumor cells have spread to the central nervous system, currently available exclusively through CNSide Diagnostics to U.S. healthcare professionals, enhancing market recognition of the test.
- Expanded Coverage: The agreement takes effect on May 1, 2026, and is expected to widen the test's availability to 126 million people, significantly boosting Plus Therapeutics' competitiveness in the cancer screening market.
- Market Impact: This agreement not only enhances Plus Therapeutics' market position but may also drive its stock price up, reflecting investor confidence in the company's future growth potential.
See More
Elevance Health and IFF Transform School Fitness Space
- Fitness Space Renovation: Thomas Carr Howe Middle School celebrated the transformation of its fitness and strength training area through a partnership with Elevance Health and the Impact Fitness Foundation, enhancing health and athletic opportunities for students.
- Ongoing Community Investment: This marks the fifth consecutive year that Elevance Health and IFF have invested in community fitness initiatives in Indianapolis schools, demonstrating the company's long-term commitment to youth health.
- Volunteer Engagement: More than 40 Elevance Health volunteers participated in the renovation, installing new flooring, fitness equipment, and storage systems to create a modern training environment aimed at supporting student wellness.
- Support for Female Athletes: The renovated facility will provide expanded opportunities for female student-athletes, helping them build confidence and leadership skills, reflecting Elevance Health's commitment to empowering women in sports.
See More
Elevance Health and IFF Transform School Fitness Space
- Community Fitness Investment: Elevance Health and the Impact Fitness Foundation have partnered for five consecutive years to invest in Indianapolis schools, enhancing health and athletic opportunities for students, reflecting the company's long-term commitment to youth health.
- Facility Modernization: The newly renovated fitness space features new flooring, fitness equipment, and storage systems, designed to provide middle school students with a modern training environment that promotes their health and athletic development.
- Expanded Student Opportunities: The renovated facility will support expanded strength and conditioning programs and open gym opportunities, helping students build healthy habits and creating new experiences for female athletes.
- Leadership and Confidence: The Impact Fitness Foundation emphasizes that creating welcoming athletic spaces can help young women discover confidence and leadership, fostering lifelong connections to health and fitness while enhancing overall community well-being.
See More
Elevance Health Invests $640 Million in Affordable Housing
- Significant Investment: Elevance Health has invested $640 million in affordable housing over the past five years, reinforcing its commitment to social determinants of health and supporting over 40,000 housing units, which is expected to significantly improve community health outcomes.
- Long-term Commitment: With over $1 billion invested in nearly two decades, the company demonstrates its ongoing efforts to lower total healthcare costs and expand access to safe, stable, and affordable housing, aiming to enhance overall community well-being.
- Social Impact: These investments not only provide economic support for housing development but also actively promote improvements in social health, helping more families secure stable living conditions that enhance their quality of life.
- Strategic Importance: This investment reflects the company's emphasis on social responsibility, aiming to reduce healthcare expenditures by improving housing conditions, thereby strengthening its competitive position and market standing in the healthcare industry.
See More
